Literature DB >> 34546213

The Natural History of Acute Radiation-induced H-ARS and Concomitant Multi-organ Injury in the Non-human Primate: The MCART Experience.

Ann M Farese1, Catherine Booth2, Greg L Tudor2, Wanchang Cui3, Eric P Cohen1, George A Parker4, Kim G Hankey1, Thomas J MacVittie1.   

Abstract

ABSTRACT: The dose response relationship and corresponding values for mid-lethal dose and slope are used to define the dose- and time-dependent parameters of the hematopoietic acute radiation syndrome. The characteristic time course of mortality, morbidity, and secondary endpoints are well defined. The concomitant comorbidities, potential mortality, and other multi-organ injuries that are similarly dose- and time-dependent are less defined. Determination of the natural history or pathophysiology associated with the lethal hematopoietic acute radiation syndrome is a significant gap in knowledge, especially when considered in the context of a nuclear weapon scenario. In this regard, the exposure is likely ill-defined, heterogenous, and nonuniform. These conditions forecast sparing of bone marrow and increased survival from the acute radiation syndrome consequent to threshold doses for the delayed effects of acute radiation exposure due to marrow sparing, medical management, and use of approved medical countermeasures. The intent herein is to provide a composite natural history of the pathophysiology concomitant with the evolution of the potentially lethal hematopoietic acute radiation syndrome derived from studies that focused on total body irradiation and partial body irradiation with bone marrow sparing. The marked differential in estimated LD50/60 from 7.5 Gy to 10.88 Gy for the total body irradiation and partial body irradiation with 5% bone marrow sparing models, respectively, provided a clear distinction between the attendant multiple organ injury and natural history of the two models that included medical management. Total body irradiation was focused on equivalent LD50/60 exposures. The 10 Gy and 11 Gy partial body with 5% bone marrow sparing exposures bracketed the LD50/60 (10.88 Gy). The incidence, progression, and duration of multiple organ injury was described for each exposure protocol within the hematopoietic acute radiation syndrome. The higher threshold doses for the partial body irradiation with bone marrow sparing protocol induced a marked degree of multiple organ injury to include lethal gastrointestinal acute radiation syndrome, prolonged crypt loss and mucosal damage, immune suppression, acute kidney injury, body weight loss, and added clinical comorbidities that defined a complex timeline of organ injury through the acute hematopoietic acute radiation syndrome. The natural history of the acute radiation syndrome presents a 60-d time segment of multi-organ sequelae that is concomitant with the latent period or time to onset of the evolving multi-organ injury of the delayed effects of acute radiation exposure.
Copyright © 2021 Health Physics Society.

Entities:  

Mesh:

Year:  2021        PMID: 34546213      PMCID: PMC8462029          DOI: 10.1097/HP.0000000000001451

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   2.922


  51 in total

1.  Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome.

Authors:  Alain Chapel; Jean Marc Bertho; Morad Bensidhoum; Loic Fouillard; Randell G Young; Johanna Frick; Christelle Demarquay; Frédérique Cuvelier; Emilie Mathieu; François Trompier; Nicolas Dudoignon; Claire Germain; Christelle Mazurier; Jocelyne Aigueperse; Jade Borneman; Norbert Claude Gorin; Patrick Gourmelon; Dominique Thierry
Journal:  J Gene Med       Date:  2003-12       Impact factor: 4.565

Review 2.  Cytokine-based treatment of accidentally irradiated victims and new approaches.

Authors:  Francis Hérodin; Michel Drouet
Journal:  Exp Hematol       Date:  2005-10       Impact factor: 3.084

3.  Subject-Based versus Population-Based Care after Radiation Exposure.

Authors:  Jiang-Zhou Yu; Matt Lindeblad; Alex Lyubimov; Flavia Neri; Brett Smith; Erzsebet Szilagyi; Lisa Halliday; Tom MacVittie; Joy Nanda; Amelia Bartholomew
Journal:  Radiat Res       Date:  2015-06-29       Impact factor: 2.841

4.  An Interlaboratory Validation of the Radiation Dose Response Relationship (DRR) for H-ARS in the Rhesus Macaque.

Authors:  Karla D Thrall; Ruschelle Love; Kyle C OʼDonnell; Ann M Farese; Ronald Manning; Thomas J MacVittie
Journal:  Health Phys       Date:  2015-11       Impact factor: 1.316

5.  A mortality determinant in nonuniform exposures of the mammal.

Authors:  V P Bond; C V Robinson
Journal:  Radiat Res Suppl       Date:  1967

6.  Total Body Irradiation in the "Hematopoietic" Dose Range Induces Substantial Intestinal Injury in Non-Human Primates.

Authors:  Junru Wang; Lijian Shao; Howard P Hendrickson; Liya Liu; Jianhui Chang; Yi Luo; John Seng; Mylene Pouliot; Simon Authier; Daohong Zhou; William Allaben; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2015-10-23       Impact factor: 2.841

7.  Severity of organ injury as a predictor of acute mortality for disparate patterns of absorbed dose distribution.

Authors:  V P Bond; A L Carsten; J Bullis; S P Roth
Journal:  Radiat Res       Date:  1991-10       Impact factor: 2.841

Review 8.  Radiation sensitivity of the hemopoietic stem cell.

Authors:  D W van Bekkum
Journal:  Radiat Res       Date:  1991-10       Impact factor: 2.841

9.  Mathematical model of radiation effects on thrombopoiesis in rhesus macaques and humans.

Authors:  J M Wentz; V Vainstein; D Oldson; Z Gluzman-Poltorak; L A Basile; D Stricklin
Journal:  J Theor Biol       Date:  2015-07-29       Impact factor: 2.691

10.  A non-human primate model of radiation-induced cachexia.

Authors:  Wanchang Cui; Alexander W Bennett; Pei Zhang; Kory R Barrow; Sean R Kearney; Kim G Hankey; Cheryl Taylor-Howell; Allison M Gibbs; Cassandra P Smith; Thomas J MacVittie
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.